(IN BRIEF) Sanofi has launched early global shipments of Beyfortus (nirsevimab) in anticipation of the 2025–2026 RSV season, enabling healthcare providers to begin immunizations well before the typical onset of infections in November. In collaboration with AstraZeneca, Sanofi has significantly … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AstraZeneca, Beyfortus, EU label, extended protection, global distribution, hospitalizations, infant immunization, lower respiratory tract disease, monoclonal antibody, newborn care, nirsevimab, pediatric health, public health, real-world studies, respiratory syncytial virus, RSV, RSV season, Sanofi, Thomas Triomphe, Vaccine Innovation, vaccine supply chain
(IN BRIEF) Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize a vaccine candidate for extraintestinal pathogenic E. coli (ExPEC) that is currently in Phase 3 of clinical trials. ExPEC … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged E. coli, E.mbrace, ExPEC, Janssen, partnership, Sanofi, SEPSIS, sustainability, Thomas Triomphe, vaccine
Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disorders Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide Sanofi to leverage its next-generation mRNA platform to unlock … Read the full press release
Posted in Austria, Business, France, Healthcare, News, Pharma & Biotech
Tagged acne, acne vulgaris, acquisition, antigens, biotechnology, Cutibacterium acnes bacterium, microbiome, mRNA, ORI-001, Origimm Biotechnology GmbH, Sanofi, Sanya Selak, skin disease, skin immunology, skin microbiome, Thomas Triomphe, virulent skin microbiome
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?